Novartis Deal History & Licensing Activity
Novartis is a large pharma headquartered in Switzerland. Over the past three years, Novartis has been involved in 32 licensing and acquisition transactions, with a primary focus on Other (12 deals). The company currently has 50 active clinical trials, primarily in Neurology.
Deals (12mo)
15
Active Trials
50
Top Modality
Other
Focus Area
Neurology
Novartis Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Novartis in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| Preclinical radioligand therapy | BoomRay Pharmaceuticals | Radiopharmaceuticals | Preclinical | license | Sep 22, 2026 |
| Blood-brain-barrier drug-delivery platform | Sironax | Other | Preclinical | option | Sep 16, 2026 |
| MRT-6160 (DDY391) | Monte Rosa Therapeutics | Small Molecules | Phase 1 | license | Sep 8, 2026 |
| drug-delivery technology platform | Alteogen | Other | Unknown | option | Sep 2, 2026 |
| Undisclosed | Chai Discovery | Antibodies | Discovery | collaboration | Jul 14, 2026 |
| undisclosed cancer target programs | Antares Therapeutics | Other | Unknown | license | Jun 24, 2026 |
| molecular glue programs | Orionis Biosciences | Small Molecules | Discovery | license | Jun 10, 2026 |
| next-generation anti-IgE therapies | Excellergy, Inc. | Antibodies | Preclinical | acquisition | Mar 27, 2026 |
| SNV4818 | Synnovation Therapeutics / Pikavation Therapeutics | Small Molecules | Phase 1 | acquisition | Mar 20, 2026 |
| Undisclosed | Unnatural Products | Peptides | Discovery | collaboration | Feb 21, 2026 |
Showing 10 of 15 recent transactions. Upgrade to Pro for full deal history with financials.
Novartis Pipeline Focus
Therapeutic areas and modalities where Novartis is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Novartis Strategic Signals
Key indicators of Novartis's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
Novartis Clinical Pipeline
Novartis has 50 active clinical trials across 7 development phases.
8
Unknown
1
Phase 4
4
Phase 1
5
Phase 1/2
16
Phase 2
1
Phase 2/3
15
Phase 3
See How Your Asset Matches Novartis's Portfolio
Use Solidus to benchmark upfront payments, milestones, and royalties for Neurology assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
Neurology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for neurology
Oncology Deal Benchmarks
Market sizing, deal terms, and competitive landscape for oncology
Other Benchmarks
Upfront, milestone, and royalty benchmarks for other deals
Antibodies Benchmarks
Upfront, milestone, and royalty benchmarks for antibodies deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 700+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Novartis Licensing & Deal Activity
Novartis is a large pharma company based in Switzerland that has been actively engaged in licensing transactions across the biopharma landscape. With 32 deals over the past three years, Novartis ranks among the most acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Novartis include Neurology (12 deals and trials), Oncology (11 deals and trials), Solid Tumors (10 deals and trials), and Cardiovascular (8 deals and trials). In terms of modality, Novartis has shown particular interest in other, antibodies, small molecules.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Novartis and 700+ other biopharma companies. Use our Solidus to benchmark your asset against Novartis's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.